In addition, Schneider and collaborators observed that RAS-mutant KMT2A-r ALL cells treated with DNA methyltransferase inhibitor decitabine in combination with the MEK inhibitor pimasertib strongly decreased cell viability compared to either drug alone. Here, MAP2K7 is linked to acute lymphoblastic leukemia.